BRD2 and pachyonychia congenita: Prostate cancer (PC) progression and recurrence remain significant clinical challenges, necessitating a multifaceted strategy to effectively intervene, where the currently available approaches that include LH/FSH modulators, anti-AR small molecules, CYP17A1 and CYP27A1 inhibitors, chemotherapies, and immunotherapies are not providing definitive curative outcomes, especially in mCRPC patients, who are susceptible to a high recurrence rate [1,2,35,36].